05 Jun Daraxonrasib Shows Meaningful Survival Benefit in Advanced Pancreatic Cancer: What Oncologists and Patients Should Know

Dr. Avishek Kumar

MedicalResearch.com Interview with:
Avishek Kumar, MD
Board-Certified Medical Oncologist and Hematologist
Edison, NJ (NYC Metro)

MedicalResearch.com: What is the background for this announcement?

Response: Pancreatic cancer has been one of the hardest cancers to treat in all of oncology.

It is often found late. It spreads early. For decades, it has not had the kind of breakthroughs we have seen in lung cancer, melanoma, breast cancer, or other tumors.

In the majority of patients with advanced pancreatic cancer, treatment has mostly meant chemotherapy. Regimens like FOLFIRINOX or gemcitabine/nab-paclitaxel can help. They can extend life. They can shrink cancer. But the benefit is often limited, and the side effects can be tough.

Once the cancer grows after first-line treatment, the options get even more narrow. That is why the daraxonrasib data matter.

Daraxonrasib, also known as RMC-6236, is an investigational oral targeted drug. It is designed to block active RAS signaling. That is a big deal because pancreatic cancer is one of the most RAS-driven cancers we see. Most pancreatic cancers have a KRAS mutation or another alteration in that pathway.

For years, KRAS was considered “undruggable.” We knew it was driving the cancer. We just did not have a good way to hit it.

This new data suggests that may be changing.

In previously treated advanced RAS-mutated pancreatic cancer, daraxonrasib appeared to improve median overall survival compared with standard chemotherapy. Reports have described survival of about 13.2 months versus 6.7 months. In pancreatic cancer, that is not a small finding. That is meaningful. Very meaningful.

MedicalResearch.com: How does this drug differ from other medications for pancreatic cancer?

Response: The main difference is that daraxonrasib is not traditional chemotherapy.

Chemotherapy attacks rapidly dividing cells. That can work, but it also hits normal cells. That is why patients can get low blood counts, infections, fatigue, neuropathy, diarrhea, nausea, weight loss, and other difficult side effects. Daraxonrasib is different. It is aimed at one of the main engines of the cancer.

A simple way to think about it: many pancreatic cancer cells have a stuck accelerator pedal. The RAS pathway keeps sending growth signals. Daraxonrasib is designed to interfere with that signal. That is a different strategy.

Not just “kill fast-growing cells.” More like, “turn down the cancer’s growth signal.” That is why oncologists are paying more attention.

It also matters because immunotherapy has been disappointing for most pancreatic cancer patients. Immunotherapy has changed lung cancer, melanoma, kidney cancer, and many others. But most pancreatic cancers do not respond well. The tumors are dense, fibrotic, and immunologically cold. They just do not behave like melanoma or lung cancer.

There are exceptions, of course. MSI-high pancreatic cancer can respond to immunotherapy. But that is a small minority.

For most patients, we have badly needed a different approach. Daraxonrasib may represent that.

Another practical point: it is an oral pill. That does not mean it is easy. Pills can have side effects too. Rash, diarrhea, mouth sores, nausea, fatigue, liver test changes — these things still matter and need close monitoring.

But for a patient with metastatic pancreatic cancer, an effective oral option can be huge. Less time in an infusion chair. More time at home. More time eating, walking, traveling, sitting with family, living. In this disease, quality of life is not a side issue. It is central.

MedicalResearch.com: Might daraxonrasib be useful in other difficult-to-treat malignancies?

Response: Possibly, yes.

RAS mutations are not only found in pancreatic cancer. They are seen in colorectal cancer, lung cancer, biliary cancers, and other tumors.

That is what makes this so interesting. If a drug can target active RAS signaling across different mutations, it may have uses beyond pancreatic cancer. But we need to be careful here. Cancer type matters. Mutation type matters. Co-mutations matter. Prior treatments matter. A drug that works in pancreatic cancer may not work the same way in colon cancer or lung cancer. That said, the concept is very exciting.

For decades, RAS was the locked door in oncology. We kept saying, “This is important, but we cannot drug it.” Now that door is opening.

KRAS G12C drugs already showed that some KRAS mutations can be targeted. Daraxonrasib may push that idea further, because it is being studied in a broader range of RAS-driven cancers. The future may be combinations. Daraxonrasib with chemotherapy. Or with other targeted drugs. Or earlier in the disease. Or after surgery. We do not know yet. But this is how progress starts. One signal. Then better trials. Then better patient selection. Then combinations. Then, hopefully, better outcomes.

For more on advances in pancreatic cancer research, see MedicalResearch.com’s cancer and oncology research coverage.

MedicalResearch.com: Is there anything else you would like to add?

Response: The biggest message for patients is this: this is real hope, but it is not a miracle pill available to everyone tomorrow.

Daraxonrasib is still investigational. Patients should not assume they can simply request it and receive it. Access may be through a clinical trial or, in some cases, an expanded access pathway. That process has to go through the treating oncologist.

So the practical advice is simple: ask your oncologist about molecular testing. Ask whether your cancer has a KRAS or RAS alteration. Ask whether a trial is available. Ask whether expanded access is reasonable in your situation. Do not wait until all options are gone to have that conversation.

This is also why molecular profiling is so important. In 2026, “pancreatic cancer” is not enough information. We need to know the biology. The mutation profile. The prior treatments. The patient’s strength and goals. That is where oncology is going.

My hope is that daraxonrasib is not just another drug announcement; I hope it is a signal that pancreatic cancer is finally entering the precision oncology era.
We still have a long way to go. Resistance will happen. Not every patient will benefit. Side effects will need to be managed, and access may be complicated at first.
Nonetheless, for a disease where progress has been painfully slow, this is a major step. And for patients and families facing pancreatic cancer, a major step matters.

Dr. Kumar

About Dr. Avishek Kumar

Dr. Avishek Kumar is a board-certified medical oncologist based in Edison, NJ (NYC metro). He focuses on modern, evidence-based cancer treatment, second opinions, and infusion therapies. He also serves as a Lieutenant Colonel in the U.S. Air Force Reserve as a flight surgeon. He has deployed overseas and regularly flies on fighter aircraft in support of operational missions, bringing a high-performance, mission-driven mindset to medicine and leadership.

Reference:

Daraxonrasib (RMC-6236) in RAS-mutated pancreatic cancer: clinical data and trial information available via the U.S. National Library of Medicine ClinicalTrials.gov registry.

Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on June 5, 2026 by Marie Benz MD FAAD